These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 11641415)
21. Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines. Shapiro GI; Koestner DA; Matranga CB; Rollins BJ Clin Cancer Res; 1999 Oct; 5(10):2925-38. PubMed ID: 10537362 [TBL] [Abstract][Full Text] [Related]
22. Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells. Motwani M; Rizzo C; Sirotnak F; She Y; Schwartz GK Mol Cancer Ther; 2003 Jun; 2(6):549-55. PubMed ID: 12813134 [TBL] [Abstract][Full Text] [Related]
23. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Motwani M; Delohery TM; Schwartz GK Clin Cancer Res; 1999 Jul; 5(7):1876-83. PubMed ID: 10430095 [TBL] [Abstract][Full Text] [Related]
24. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process. Dai Y; Rahmani M; Grant S Oncogene; 2003 Oct; 22(46):7108-22. PubMed ID: 14562039 [TBL] [Abstract][Full Text] [Related]
25. Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phase. Matranga CB; Shapiro GI Cancer Res; 2002 Mar; 62(6):1707-17. PubMed ID: 11912144 [TBL] [Abstract][Full Text] [Related]
26. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Shapiro GI Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4270s-4275s. PubMed ID: 15217973 [TBL] [Abstract][Full Text] [Related]
27. Growth inhibition and induction of apoptosis by flavopiridol in rat lung adenocarcinoma, osteosarcoma and malignant fibrous histiocytoma cell lines. Honoki K; Yoshitani K; Tsujiuchi T; Mori T; Tsutsumi M; Morishita T; Takakura Y; Mii Y Oncol Rep; 2004 May; 11(5):1025-30. PubMed ID: 15069542 [TBL] [Abstract][Full Text] [Related]
28. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. Schwartz GK; Farsi K; Maslak P; Kelsen DP; Spriggs D Clin Cancer Res; 1997 Sep; 3(9):1467-72. PubMed ID: 9815832 [TBL] [Abstract][Full Text] [Related]
29. Flavopiridol, an inhibitor of cyclin-dependent kinases, induces growth inhibition and apoptosis in bladder cancer cells in vitro and in vivo. Wirger A; Perabo FG; Burgemeister S; Haase L; Schmidt DH; Doehn C; Mueller SC; Jocham D Anticancer Res; 2005; 25(6B):4341-7. PubMed ID: 16309238 [TBL] [Abstract][Full Text] [Related]
30. Rhabdoid tumor growth is inhibited by flavopiridol. Smith ME; Cimica V; Chinni S; Challagulla K; Mani S; Kalpana GV Clin Cancer Res; 2008 Jan; 14(2):523-32. PubMed ID: 18223228 [TBL] [Abstract][Full Text] [Related]
31. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Carlson B; Lahusen T; Singh S; Loaiza-Perez A; Worland PJ; Pestell R; Albanese C; Sausville EA; Senderowicz AM Cancer Res; 1999 Sep; 59(18):4634-41. PubMed ID: 10493518 [TBL] [Abstract][Full Text] [Related]
32. Cell cycle-independent induction of apoptosis by the anti-tumor drug Flavopiridol in endothelial cells. Brüsselbach S; Nettelbeck DM; Sedlacek HH; Müller R Int J Cancer; 1998 Jul; 77(1):146-52. PubMed ID: 9639406 [TBL] [Abstract][Full Text] [Related]
33. The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity. Bonvini P; Zorzi E; Mussolin L; Monaco G; Pigazzi M; Basso G; Rosolen A Haematologica; 2009 Jul; 94(7):944-55. PubMed ID: 19535344 [TBL] [Abstract][Full Text] [Related]
34. Potent interaction of flavopiridol with MRP1. Hooijberg JH; Broxterman HJ; Scheffer GL; Vrasdonk C; Heijn M; de Jong MC; Scheper RJ; Lankelma J; Pinedo HM Br J Cancer; 1999 Sep; 81(2):269-76. PubMed ID: 10496352 [TBL] [Abstract][Full Text] [Related]
35. Flavopiridol as a radio-sensitizer for esophageal cancer cell lines. Sato S; Kajiyama Y; Sugano M; Iwanuma Y; Tsurumaru M Dis Esophagus; 2004; 17(4):338-44. PubMed ID: 15569374 [TBL] [Abstract][Full Text] [Related]
36. Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies. Senderowicz AM Leukemia; 2001 Jan; 15(1):1-9. PubMed ID: 11243375 [TBL] [Abstract][Full Text] [Related]
38. Induction of apoptosis and down regulation of cell cycle proteins in mantle cell lymphoma by flavopiridol treatment. Venkataraman G; Maududi T; Ozpuyan F; Bahar HI; Izban KF; Qin JZ; Alkan S Leuk Res; 2006 Nov; 30(11):1377-84. PubMed ID: 16624404 [TBL] [Abstract][Full Text] [Related]
39. Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity. Li W; Fan J; Bertino JR Cancer Res; 2001 Mar; 61(6):2579-82. PubMed ID: 11289134 [TBL] [Abstract][Full Text] [Related]
40. Tangeretin induces cell-cycle G1 arrest through inhibiting cyclin-dependent kinases 2 and 4 activities as well as elevating Cdk inhibitors p21 and p27 in human colorectal carcinoma cells. Pan MH; Chen WJ; Lin-Shiau SY; Ho CT; Lin JK Carcinogenesis; 2002 Oct; 23(10):1677-84. PubMed ID: 12376477 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]